Protara Therapeutics (TARA) Other Accumulated Expenses (2013 - 2026)

Protara Therapeutics (TARA) has 12 years of Other Accumulated Expenses data on file, last reported at $176000.0 in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 22.12% year-over-year to $176000.0 in Q1 2026; TTM through Mar 2026 was $176000.0, a 22.12% decrease from a year earlier, with the FY2025 full-year figure at $279000.0, up 106.67% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $176000.0, down from $279000.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for TARA reached as high as $368000.0 in Q3 2024 and fell as low as $79000.0 in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $192235.3 across 5 years, with a median of $178000.0 in 2022.
• Across the five-year window, Other Accumulated Expenses sank 71.99% in 2022 and surged 354.32% in 2024, its largest moves.
• Year by year, Other Accumulated Expenses stood at $182000.0 in 2022, then decreased by 1.1% to $180000.0 in 2023, then slipped by 25.0% to $135000.0 in 2024, then soared by 106.67% to $279000.0 in 2025, then tumbled by 36.92% to $176000.0 in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $176000.0 in Q1 2026, $279000.0 in Q4 2025, and $329000.0 in Q3 2025.